Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMPWBNU)

• Drug Name: L-755507 Drug Info
• Synonyms: 159182-43-1; L755507; L-755,507; CHEMBL12998; 4-[[(HEXYLAMINO)CARBONYL]AMINO]-N-[4-[2-[[(2S)-2-HYDROXY-3-(4-HYDROXYPHENOXY)PROPYL]AMINO]ETHYL]PHENYL]-BENZENESULFONAMIDE; L 755507; SCHEMBL5165122; GTPL3931; MolPort-003-983-607; ZINC3939153; EX-A2397; s7974; BDBM50070156; AKOS024456983; CP-0074; CS-7782; NCGC00092331-01; HY-19334; F10055; L755507, > J-009574; L-755 507; (S)-4-(3-hexylureido)-N-(4-(2-(1-hydroxy-2-(4-hydroxyphenoxy)ethylamino)ethyl)phenyl)benzenesulfonamide
• Cross-matching ID:
  PubChem CID: 9829836
  CAS Number: CAS 159182-43-1
  TTD Drug ID: DMPWBNU

Molecule-Related Drug Atlas

Drug(s) Targeting Trypanosoma Cruzipain (Trypano CYSP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
TRICLABENDAZOLE	DMPWGBR	Helminth infection	1F90.0	Approved	[3]
MANIDIPINE	DMJPGUA	N. A.	N. A.	Phase 3	[3]
GNF-PF-4478	DMCDU8K	Discovery agent	N.A.	Investigative	[4]
K-777	DMIFCMW	Discovery agent	N.A.	Investigative	[5]
WRR-99	DM8ZA6K	Discovery agent	N.A.	Investigative	[6]
Benzoyl-Arginine-Alanine-Methyl Ketone	DMC7TNF	Discovery agent	N.A.	Investigative	[6]
Vinylsulphones	DMNFVO7	Infection of P. falciparum	1F40	Investigative	[7]
WRR-112	DMP761U	Discovery agent	N.A.	Investigative	[6]
1-(3-Methoxy-benzyl)-5-methyl-1H-indole-2,3-dione	DM30M9H	Discovery agent	N.A.	Investigative	[8]
3-amino-5-(furan-2-yl)biphenyl-2,4-dicarbonitrile	DM6Y2KW	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Adrenergic receptor beta-1 (ADRB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[9]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[10]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[11]
Atenolol	DMNKG1Z	Angina pectoris	BA40	Approved	[12]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[12]
Metoprolol	DMOJ0V6	Acute coronary syndrome	BA41	Approved	[12]
Timolol	DM3NXRU	High blood pressure	BA00	Approved	[13]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[14]
Betaxolol	DM6EUL5	Hypertension	BA00-BA04	Approved	[15]
Sotalol	DML60TN	Sinus rhythm disorder	BC9Y	Approved	[16]

Drug(s) Targeting Adrenergic receptor beta-2 (ADRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Indacaterol	DMQJHR7	Chronic obstructive pulmonary disease	CA22	Approved	[17]
Formoterol	DMSOURV	Allergic asthma	CA23.0	Approved	[18]
Salbutamol	DMN9CWF	Acute asthma	CA23	Approved	[19]
Arformoterol	DMYM974	Chronic obstructive pulmonary disease	CA22	Approved	[20]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[14]
Salmeterol	DMIEU69	Allergic asthma	CA23.0	Approved	[21]
Clenbuterol	DMCKYZ5	Chronic breathing disorder	7A4Z	Approved	[22]
Ritodrine	DM4V6RL	Premature labour	JB00	Approved	[23]
Olodaterol	DM62B78	Chronic obstructive pulmonary disease	CA22	Approved	[24]
Fenoterol	DMIP3ZV	Asthma	CA23	Approved	[25]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Inhibitor	[1]
Adrenergic receptor beta-2 (ADRB2)	TT2CJVK	ADRB2_HUMAN	Inhibitor	[1]
Trypanosoma Cruzipain (Trypano CYSP)	TTEAID7	CYSP_TRYCR	Inhibitor	[2]

References

• [1] (4-Piperidin-1-yl)phenyl amides: potent and selective human beta(3) agonists. J Med Chem. 2001 Apr 26;44(9):1456-66.
• [2] Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. J Med Chem. 2010 Jan 14;53(1):37-51.
• [3] Colloid formation by drugs in simulated intestinal fluid. J Med Chem. 2010 May 27;53(10):4259-65.
• [4] Complementarity between a docking and a high-throughput screen in discovering new cruzain inhibitors. J Med Chem. 2010 Jul 8;53(13):4891-905.
• [5] Novel non-peptidic vinylsulfones targeting the S2 and S3 subsites of parasite cysteine proteases. Bioorg Med Chem Lett. 2009 Nov 1;19(21):6218-21.
• [6] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [7] Opportunities and challenges in antiparasitic drug discovery. Nat Rev Drug Discov. 2005 Sep;4(9):727-40.
• [8] Synthesis and evaluation of isatins and thiosemicarbazone derivatives against cruzain, falcipain-2 and rhodesain. Bioorg Med Chem Lett. 2003 Oct 20;13(20):3527-30.
• [9] Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
• [10] Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
• [11] Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
• [12] Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
• [13] Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
• [14] Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
• [15] beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
• [16] beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
• [17] Emerging drugs in chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2009 Mar;14(1):181-94.
• [18] Long-acting beta2-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev. 2002;(3):CD001104.
• [19] Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002;16(1):1-8.
• [20] Arformoterol tartrate in the treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease. Drugs Today (Barc). 2009 Jan;45(1):3-9.
• [21] Pharmacogenetic tests in asthma therapy. Clin Lab Med. 2008 Dec;28(4):645-65.
• [22] Postischemic brain injury is attenuated in mice lacking the beta2-adrenergic receptor. Anesth Analg. 2009 Jan;108(1):280-7.
• [23] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [24] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [25] Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol. 2009 Jul;220(1):267-75.